NCT02115204View on ClinicalTrials.gov

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

PHASE3CompletedINTERVENTIONAL
Enrollment

2,011

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2010

Conditions
Breast Cancer
Interventions
DRUG

Epirubicin

DRUG

Cyclophosphamide

DRUG

Docetaxel

DRUG

Methotrexate

DRUG

5-fluorouracil

Trial Locations (1)

41061

Ev. Hospital Bethesda, Mönchengladbach

All Listed Sponsors
collaborator

AGO Germany

UNKNOWN

lead

West German Study Group

OTHER

NCT02115204 - 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF | Biotech Hunter | Biotech Hunter